Special Issue

Diagnosis, Resistance and Treatment of Infections by Candida auris

Message from the Guest Editor

Candida auris is an emerging and multidrug-resistant yeast that can spread in healthcare settings. The microorganism can cause bloodstream and other types of invasive infections, principally in patients in hospitals and nursing homes who are affected with diseases. Screening patients for *C. auris* colonization allows facilities to identify those with it colonization and implements infection prevention and control measures. Nevertheless. *C. auris* is important to identify even from a nonsterile body site because the presence of *C. auris* in any body site can suggest broader colonization. Based on this evidence, the healthcare and scientific communities should consider C. auris as one of the most serious emerging pathogen. The aim of this Issue is to offer the possibility to publish papers focusing on clinical and microbiological characteristics, mechanisms of virulence, antifungal resistance, efficacy of available control, and preventive and therapeutic strategies to treat C. auris infections. Keywords: C. auris rapid identification; drug resistant; therapeutic strategies; screening

Guest Editor

Prof. Dr. Anna Giammanco

Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialities, University of Palermo, 90127 Palermo, Italy

Deadline for manuscript submissions

closed (31 July 2020)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/39478

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

